Upstream Bio outlines Phase 3 plans for verekitug in asthma and CRSwNP
Upstream Bio says it will study 400 mg verekitug every 12 weeks versus placebo in severe asthma and CRSwNP, using one pivotal Phase 3 trial per indication after FDA discussions.
Following discussions with the FDA, Upstream Bio said it will study 400 mg of verekitug given every 12 weeks versus placebo in severe asthma and CRSwNP, with one pivotal Phase 3 trial planned in each indication. The company said its Phase 3 strategy is intended to deliver best-in-class efficacy across both…